ArticleCureus2025
Anti-N-Methyl-D-Aspartate Receptor Encephalitis Associated With Small Cell Lung Cancer: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-N-methyl-d-aspartate receptor encephalitis (NMDARE) is an autoimmune disorder with a clinical presentation that overlaps with that of a myriad of neuropsychiatric conditions. Delays in diagnosis have been linked to long-term complications that affect a patient's quality of life. A 60-year-old female patient with a medical history of emphysema with chronic respiratory failure, hypertension, diabetes, morbid obesity, and hyperlipidemia presented to the hospital after she was found confused at home with limited verbal output, raising concerns for cerebrovascular events or toxic metabolic encephalitis. Neuroimaging and EEG results were unremarkable. The patient continued to experience respiratory distress that delayed diagnostic procedures. She was later diagnosed with small-cell lung cancer, and cerebrospinal fluid tests were positive for anti-N-methyl-d-aspartate receptor antibodies. Gradual improvement in cognitive function and speech was noted after treatment with immunotherapy. This case study underscores the importance of considering rare neurological conditions in patients with heightened cardiovascular risk profiles. Furthermore, it provides insights into the potential diagnostic and therapeutic challenges that can arise in the domain of anti-NMDARE in such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.